HIV risk reduction in the National Institute on Drug Abuse cocaine collaborative treatment study

George E. Woody, Robert Gallop, Lester Luborsky, Jack Blaine, Arlene Frank, Ihsan M Salloum, David Gastfriend, Paul Crits-Christoph

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

HIV risk was evaluated among 487 cocaine-dependent patients recruited from five treatment programs in a trial that examined the efficacy of four outpatient-based psychosocial treatments. Treatments were offered two to three times per week for 6 months and consisted of group drug counseling (GDC) or group counseling plus individual drug counseling (IDC), cognitive therapy (CT), or supportive-expressive therapy (SE). The average patient had used cocaine for 7 years, with 10 days of use in the last month. Crack smoking was the main route in 79%, and HIV risk was mainly due to multiple partners and unprotected sex. Treatment was associated with a decrease in cocaine use from an average of 10 days per month at baseline to 1 day per month at 6 months. Reduction in cocaine use was associated with an average 40% decrease in HIV risk across all treatment, gender, and ethnic groups, mainly as a result of fewer sexual partners and less unprotected sex. The combination of IDC and GDC was associated with an equal or even greater reduction in HIV risk than the other treatment conditions and thus shows promise as an effective HIV prevention strategy, at least for some patients.

Original languageEnglish
Pages (from-to)82-87
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume33
Issue number1
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

National Institute on Drug Abuse (U.S.)
Risk Reduction Behavior
Cocaine
HIV
Counseling
Unsafe Sex
Sexual Partners
Therapeutics
Pharmaceutical Preparations
Cognitive Therapy
Drug Combinations
Ethnic Groups
Outpatients
Smoking

Keywords

  • Cocaine dependence
  • HIV risk

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Woody, G. E., Gallop, R., Luborsky, L., Blaine, J., Frank, A., Salloum, I. M., ... Crits-Christoph, P. (2003). HIV risk reduction in the National Institute on Drug Abuse cocaine collaborative treatment study. Journal of Acquired Immune Deficiency Syndromes, 33(1), 82-87.

HIV risk reduction in the National Institute on Drug Abuse cocaine collaborative treatment study. / Woody, George E.; Gallop, Robert; Luborsky, Lester; Blaine, Jack; Frank, Arlene; Salloum, Ihsan M; Gastfriend, David; Crits-Christoph, Paul.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 33, No. 1, 01.05.2003, p. 82-87.

Research output: Contribution to journalArticle

Woody, GE, Gallop, R, Luborsky, L, Blaine, J, Frank, A, Salloum, IM, Gastfriend, D & Crits-Christoph, P 2003, 'HIV risk reduction in the National Institute on Drug Abuse cocaine collaborative treatment study', Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 1, pp. 82-87.
Woody, George E. ; Gallop, Robert ; Luborsky, Lester ; Blaine, Jack ; Frank, Arlene ; Salloum, Ihsan M ; Gastfriend, David ; Crits-Christoph, Paul. / HIV risk reduction in the National Institute on Drug Abuse cocaine collaborative treatment study. In: Journal of Acquired Immune Deficiency Syndromes. 2003 ; Vol. 33, No. 1. pp. 82-87.
@article{89b3df4a50114abba6c71a5485dce6ea,
title = "HIV risk reduction in the National Institute on Drug Abuse cocaine collaborative treatment study",
abstract = "HIV risk was evaluated among 487 cocaine-dependent patients recruited from five treatment programs in a trial that examined the efficacy of four outpatient-based psychosocial treatments. Treatments were offered two to three times per week for 6 months and consisted of group drug counseling (GDC) or group counseling plus individual drug counseling (IDC), cognitive therapy (CT), or supportive-expressive therapy (SE). The average patient had used cocaine for 7 years, with 10 days of use in the last month. Crack smoking was the main route in 79{\%}, and HIV risk was mainly due to multiple partners and unprotected sex. Treatment was associated with a decrease in cocaine use from an average of 10 days per month at baseline to 1 day per month at 6 months. Reduction in cocaine use was associated with an average 40{\%} decrease in HIV risk across all treatment, gender, and ethnic groups, mainly as a result of fewer sexual partners and less unprotected sex. The combination of IDC and GDC was associated with an equal or even greater reduction in HIV risk than the other treatment conditions and thus shows promise as an effective HIV prevention strategy, at least for some patients.",
keywords = "Cocaine dependence, HIV risk",
author = "Woody, {George E.} and Robert Gallop and Lester Luborsky and Jack Blaine and Arlene Frank and Salloum, {Ihsan M} and David Gastfriend and Paul Crits-Christoph",
year = "2003",
month = "5",
day = "1",
language = "English",
volume = "33",
pages = "82--87",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "1",

}

TY - JOUR

T1 - HIV risk reduction in the National Institute on Drug Abuse cocaine collaborative treatment study

AU - Woody, George E.

AU - Gallop, Robert

AU - Luborsky, Lester

AU - Blaine, Jack

AU - Frank, Arlene

AU - Salloum, Ihsan M

AU - Gastfriend, David

AU - Crits-Christoph, Paul

PY - 2003/5/1

Y1 - 2003/5/1

N2 - HIV risk was evaluated among 487 cocaine-dependent patients recruited from five treatment programs in a trial that examined the efficacy of four outpatient-based psychosocial treatments. Treatments were offered two to three times per week for 6 months and consisted of group drug counseling (GDC) or group counseling plus individual drug counseling (IDC), cognitive therapy (CT), or supportive-expressive therapy (SE). The average patient had used cocaine for 7 years, with 10 days of use in the last month. Crack smoking was the main route in 79%, and HIV risk was mainly due to multiple partners and unprotected sex. Treatment was associated with a decrease in cocaine use from an average of 10 days per month at baseline to 1 day per month at 6 months. Reduction in cocaine use was associated with an average 40% decrease in HIV risk across all treatment, gender, and ethnic groups, mainly as a result of fewer sexual partners and less unprotected sex. The combination of IDC and GDC was associated with an equal or even greater reduction in HIV risk than the other treatment conditions and thus shows promise as an effective HIV prevention strategy, at least for some patients.

AB - HIV risk was evaluated among 487 cocaine-dependent patients recruited from five treatment programs in a trial that examined the efficacy of four outpatient-based psychosocial treatments. Treatments were offered two to three times per week for 6 months and consisted of group drug counseling (GDC) or group counseling plus individual drug counseling (IDC), cognitive therapy (CT), or supportive-expressive therapy (SE). The average patient had used cocaine for 7 years, with 10 days of use in the last month. Crack smoking was the main route in 79%, and HIV risk was mainly due to multiple partners and unprotected sex. Treatment was associated with a decrease in cocaine use from an average of 10 days per month at baseline to 1 day per month at 6 months. Reduction in cocaine use was associated with an average 40% decrease in HIV risk across all treatment, gender, and ethnic groups, mainly as a result of fewer sexual partners and less unprotected sex. The combination of IDC and GDC was associated with an equal or even greater reduction in HIV risk than the other treatment conditions and thus shows promise as an effective HIV prevention strategy, at least for some patients.

KW - Cocaine dependence

KW - HIV risk

UR - http://www.scopus.com/inward/record.url?scp=0038372699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038372699&partnerID=8YFLogxK

M3 - Article

C2 - 12792359

AN - SCOPUS:0038372699

VL - 33

SP - 82

EP - 87

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 1

ER -